View metadata

dc.titleBreve 12: The "Cancer Industry" and the Pharmaceutical Policy in Germany
dc.contributor.authorInter-American Development Bank
dc.contributor.orgunitSocial Protection and Health Division
dc.coverageGermany
dc.date.available2016-07-13T00:00:00
dc.date.issue2016-07-11T00:00:00
dc.description.abstractThe following Breve provides an overview of the main challenges that societies, health care systems, and policy makers are currently facing to confront cancer. This brief analyzes the main characteristics of cancer, and shows how these influence the development of new drugs. At the same time, it looks at some of the implications for patients. It also presents some thoughts on the pharmaceutical industry related to cancer treatments. Finally, it summarizes some policy lessons emerging from the analysis, and explains why basic research, better market regulation and a stronger focus on cancer prevention should be the main priorities to fight cancer in the future.
dc.identifier.doihttp://dx.doi.org/10.18235/0007990
dc.identifier.urlhttps://publications.iadb.org/publications/english/document/Breve-12-The-Cancer-Industry-and-the-Pharmaceutical-Policy-in-Germany.pdf
dc.language.isoen
dc.mediumAdobe PDF
dc.publisherInter-American Development Bank
dc.relation.seriesCriteria Network
dc.subjectCancer Incidence
dc.subjectCancer Treatment
dc.subjectLife Expectancy
dc.subjectHealth Insurance Coverage
dc.subjectHealth Services
dc.subjectHealth Expenditure
dc.subjectHealth Policy
dc.subjectPharmaceutical Policy
dc.subject.keywordscancer treatment;cancer incidence
dc.typeLearning Materials
idb.identifier.pubnumberLearning Materials
idb.operationRG-T1759
Return to Publication